Homologous Repair‐Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy
United European Gastroenterology Journal · 2025-09 · 13 (7) · 1328-1342
DOI: 10.1002/ueg2.12773 ↗Kurz gefasst
Fachartikel in der Zeitschrift United European Gastroenterology Journal, online erschienen am 18.08.2025. Verfasst von Alica K Beutel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, University Hospital Ulm, Ulm, Germany. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Carcinoma, Pancreatic Ductal, DNA Damage. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ulm University and the German Cancer Aid, NCI NIH HHS, Sachbeihilfe.
Abstract (Originalsprache)
Background
Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with a high mortality rate. While up to 20% of PDAC patients harbor mutations in genes involved in homologous recombination (HR) repair, only 5% of germline BRCA1/2 mutation carriers have an approved treatment option with the PARP inhibitor (PARPi) olaparib. Characterizing HR‐deficient (HRD) genotypes beyond g BRCA1/2 that are susceptible to PARPi has potential to substantially broaden the eligible patient population, and defining the optimal inhibitor may further optimize treatment strategies to advance personalized medicine in PDAC.
Objective
Our previous preclinical work showed synthetic lethality of a multi‐pronged DNA damage repair interference strategy using the PARPi olaparib, ATR inhibitor VE‐822, and DNA‐PK inhibitor CC‐115 (termed PAD) in ATM deficiency. In the present study, we challenged the role of olaparib in our PAD combination and assessed the regimen's efficacy across various HRD genotypes.
Methods
We assessed a spectrum of DNA damage repair‐interfering drugs to identify the most potent inhibitor in HRD. Using ATM , BRCA1 , BRCA2 and PALB2 ‐defective versus HR‐proficient murine PDAC cells, we systematically investigated the feasibility of expanding an optimized PAD regimen within defined HRD genotypes in vitro and in vivo. The regimen's efficacy was validated in PDAC patient‐derived organoids with and without deleterious class IV/V alterations in HRD genes. Results and Conclusion Here, we demonstrate a remarkable potency of the PARPi talazoparib in HRD PDAC. Substituting olaparib, currently the only approved inhibitor in PDAC, with talazoparib in our PAD regimen enhanced its efficacy while maintaining comparable tolerability in vivo. Importantly, we show that PAD is an effective therapeutic regimen that can be extended to the most prevalent HR‐defective genotypes in PDAC including ATM , BRCA1 , BRCA2 and PALB2 in a preclinical setting. Collectively, these data provide a strong rationale to implement the refined regimen, talazoparib‐based PAD, as a therapeutic concept tailored for HRD PDAC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine I, University Hospital Ulm, Ulm, Germany.
- Department of Molecular Biology and Biochemistry, University of California Irvine, Irvine, California, USA.
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California, USA.
- Institute of Molecular Oncology and Stem Cell Biology, Ulm University Hospital, Ulm, Germany.
- Core Facility Organoids, Ulm University, Ulm, Germany.
- Division of Interdisciplinary Pancreatology, Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany.
ORCID-Profile: Alica K Beutel, Christopher J Halbrook, Menar Ekizce, Jessica Lindenmayer, Elodie Roger, Thomas Seufferlein, Alexander Kleger, Johann Gout, Lukas Perkhofer
Förderung
- Ulm University and the German Cancer Aid
- NCI NIH HHS
- Sachbeihilfe
- V Scholar award
- Sky Foundation Research Grant
- German Cancer Aid
- "Bausteinprogramm" of Ulm University
- Heisenberg-Programm
Zitieren
APA
Beutel, A. K., Halbrook, C. J., Ekizce, M., Lindenmayer, J., Roger, E., Calderon, S. E., Seufferlein, T., Kleger, A., Gout, J., & Perkhofer, L. (2025). Homologous Repair‐Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy. United European Gastroenterology Journal, 13(7), 1328-1342. https://doi.org/10.1002/ueg2.12773
Vancouver
Beutel AK, Halbrook CJ, Ekizce M, Lindenmayer J, Roger E, Calderon SE, et al. Homologous Repair‐Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy. United European Gastroenterology Journal. 2025;13(7):1328-1342. doi:10.1002/ueg2.12773
BibTeX
@article{Beutel2025,
author = {Beutel, Alica K and Halbrook, Christopher J and Ekizce, Menar and Lindenmayer, Jessica and Roger, Elodie and Calderon, Sabrina E and Seufferlein, Thomas and Kleger, Alexander and Gout, Johann and Perkhofer, Lukas},
title = {Homologous Repair‐Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy},
journal = {United European Gastroenterology Journal},
year = {2025},
volume = {13},
number = {7},
pages = {1328--1342},
doi = {10.1002/ueg2.12773}
}
EUVIMED